Rectal indomethacin reduces post-ERCP pancreatitis

In this large trial of patients undergoing ERCP, they were randomized to a single dose of rectal indomethacin or placebo immediately after the procedure; pancreatitis occurred in7 1% of those with placebo, and 9% of those with indomethacin (and moderate-to-severe pancreatitis occurred in 9% and 4% of patients, respectively). In patients at risk for post-ERCP pancreatitis, post procedure rectal indomethacin can almost halve the risk (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment